Atea reports Q4/FY2024 results; cash at $454.7M; HCV Phase 3 starts April 2025

Atea Pharmaceuticals, Inc.

Net loss per share Q4 2024 improved to ($0.40) from ($0.47); full year net loss per share ($2.00) vs ($1.63).
Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024 vs $578.1M year earlier.
Successful End-of-Phase 2 FDA meeting for HCV regimen bemnifosbuvir/ruzasvir; Phase 3 enrollment expected April 2025.
Reduced workforce by 25% in Q1 2025 to achieve ~$15M in cost savings through 2027.
Engaged Evercore for strategic partnerships for HCV Phase 3 program; appointed Arthur S. Kirsch to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.